Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 17/20 | 0.55 |
| ▸ | RAF1 | P04049 | 2/20 | 0.49 |
| ▸ | BRAF | P15056 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3475394 | 0.86 | P2RY1 (0.57) | P2RY1RAF1BRAF | |
| SCHEMBL5032974 | 0.81 | P2RY1 (0.57) | P2RY1 | |
| SCHEMBL1307144 | 0.78 | P2RY1 (0.55) | P2RY1RAF1BRAF | |
| SCHEMBL5043310 | 0.74 | P2RY1 (0.51) | P2RY1 | |
| SCHEMBL28664836 | 0.74 | P2RY1 (0.63) | P2RY1KDM4EMEN1KMT2A | |
| SCHEMBL3150780 | 0.71 | P2RY1 (1.00) | P2RY1 | |
| SCHEMBL1308243 | 0.71 | P2RY1 (0.57) | P2RY1 | |
| SCHEMBL1308211 | 0.71 | P2RY1 (0.64) | P2RY1KDM4EMEN1KMT2A | |
| SCHEMBL1324768 | 0.71 | P2RY1 (0.64) | P2RY1KDM4EMEN1KMT2A | |
| SCHEMBL5028157 | 0.70 | P2RY1 (0.56) | P2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1706398-B1 | Amino-benzazoles as P2Y1 receptor inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-05-21 | — | — | EP | claimed |
| US-20080275090-A1 | AMINO-BENZAZOLES AS P2Y1 RECEPTOR INHIBITORS WITH PYRIDINE RING AND HETEROCYCLIC COMPONENTS | BRISTOL-MYERS SQUIBB COMPANY | 2008-11-06 | — | — | US | claimed |
| JP-2007518809-A | — | — | 2007-07-12 | — | — | JP | claimed |
| EP-1706398-A1 | AMINO-BENZAZOLES AS P2Y1 RECEPTOR INHIBITORS | Bristol-Myers Squibb Pharma Company (US) | 2006-10-04 | — | — | EP | claimed |
| US-20050203146-A1 | Amino-benzazoles as P2Y1 receptor inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-09-15 | — | — | US | claimed |
| WO-2005070920-A1 | AMINO-BENZAZOLES AS P2Y1 RECEPTOR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-08-04 | — | — | WO | claimed |
| EP-1706398-B1 | Amino-benzazoles as P2Y1 receptor inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-05-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203146-A1 | Amino-benzazoles as P2Y1 receptor inhibitors | P2RY1, P2RY11, P2RY2 | P2RY1 1/4885RAF1 1696/4885BRAF 2474/4885 |
| US-20080275090-A1 | AMINO-BENZAZOLES AS P2Y1 RECEPTOR INHIBITORS WITH PYRIDINE RING AND HETEROCYCLIC COMPONENTS | P2RY1, P2RY11, P2RY2 | P2RY1 1/4885RAF1 1434/4885BRAF 1990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.